STAT3 and neoplasm: Collectively, small molecule drugs targeting JAK/STAT3/PD-L1 signal transduction or enhancing T cell cytotoxic responses exert antitumor effects by enhancing immune surveillance of tumor cells, inhibiting the immunosuppressive function of neutrophils, and ameliorating immunotherapy-induced drug responsiveness.